Generate Biomedicines is developing golukibart (GB-0895), a long-acting biologic for asthma designed for twice-yearly dosing and broad patient effectiveness. The company leads the race for TSLP antagonists with two global Phase 3 trials underway, aiming to compete with existing treatments like Tezspire and tap into the large asthma and COPD markets. Their cash runway extends into early 2028, but investors should watch for risks including high Phase 3 trial costs and possible dilution before topline data release. Despite trading at a premium, Generate Biomedicines' pipeline and platform are valued comparably to less mature assets recently acquired by big pharma, highlighting its potential.
Generate Biomedicines is the subject of this update, with Pluang market data providing context. As of Oct 13, 2026 18:02 WIB, 78 of 128 priced Health-sector US stocks rose while 41 fell. Notable movers include BioNTech SE (BNTX) at USD 93.03 with a -2.93% change and a typical hold time of 60 days on Pluang.
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, with payment on October 15, 2026. The distributions vary by ETF, reflecting different distribution rates and 30-day SEC yields, ranging from about 23% to over 60%. These ETFs cover s...
Foresight Autonomous Holdings has signed a non-binding term sheet to acquire a 50.01% controlling interest in a company developing two data center projects in Warsaw and Wroclaw, Poland, with a combined planned capacity of 270 MW. This move aligns wi...
The Asia-Pacific sustainable data center market is projected to grow from $16.74 billion in 2025 to $57.18 billion by 2031, at a CAGR of 22.7%. Growth is fueled by rising demand for AI, cloud computing, and hyperscale infrastructure, prompting invest...
Holafly has introduced the Ultra Plan, a new global eSIM subscription that offers unlimited mobile data alongside health and wellness services, including 24/7 medical messaging, mental health sessions, nutrition and fitness coaching, and veterinary a...
Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, sold 2,013 ordinary shares at a price of 1,230 per share on October 12, 2026. This transaction was disclosed under the Takeover Code, indicating a client-serving capacity trade ...
